Researchers conducted a retrospective study assessing how gene co-mutations and NPM1 measurable residual disease (MRD) affect outcomes in patients with acute myeloid leukemia (AML), mainly focusing on ...

Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to ...

High-throughput techniques to analyze the AML genome in greater depth have revealed novel mutations with putative roles in leukemogenesis. The use of prognostic biomarkers has allowed for a more ...

In May 2024, Kura Oncology announced completion of enrollment in the Phase 2 portion of KOMET-001, a registration-directed trial of ziftomenib in patients with R/R NPM1-mutant AML. Enrollment of the ...

“Because 78% of the older patients given LIT is classified as adverse-risk by 2022 ELN, we investigated the impact of molecular abnormalities to improve the ability to risk stratify ND AML ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

The menin pathway is considered a driver for multiple genetic alterations of the disease, of which NPM1 mutations are among the most common, representing approximately 30% of AML cases.